SciFi Futures
← Concepts
Biotech & Medicine

Revival of the cryopreserved dead

People frozen at the moment of death, stored for centuries, and later thawed, repaired and restored to life in a future with better medicine.

In shortRevival of the cryopreserved dead, from A World Out of Time (Larry Niven, 1976) and Revelation Space (Alastair Reynolds, 2000), is at technology readiness level 1 of 9 (basic principles observed) at its weakest link. Held back by Cell-by-cell in-vivo repair and Desktop molecular assembler. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $13B–138B (a floor; some parts are priced only to early research).

Jaybee Corbell is a corpsicle - frozen in 1970 after terminal cancer, thawed three centuries later by the State, his mind restored into a donor body and sent out as a rammer pilot.
A World Out of Time by Larry Niven, 1976Set in 2190On track164 years left to climb 7 TRL steps (23.4 yrs/step)
Long-dead or dying individuals held in cryogenic storage are revived generations later as a routine, if risky, procedure.
Revelation Space by Alastair Reynolds, 2000Set in 2566On track540 years left to climb 7 TRL steps (77.1 yrs/step)

Closest todayCryonics organizations preserve bodies today using vitrification agents; no mammal, and no mammalian brain, has been cryopreserved and functionally revived, and current preservation is a one-way procedure.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • criticalCell-by-cell in-vivo repairbottleneck
    Preservation happens after ischemic injury, so revival means repairing damage that was present before cooling, cell by cell
    • No way to read the internal state of a living cell without destroying it
    • A human body has roughly 3x10^13 cells, so any per-cell procedure needs a throughput no proposed system approaches
    • Molecular-scale positional control in a warm, crowded, aqueous environment is unsolved
    • Energy supply and waste handling for billions of simultaneously operating devices is unaddressed
    plausibleTRL 1
    • Rebuilding damaged structures implies atomically precise construction under program control
      • Requires positional mechanosynthesis at ~10^6 operations/s per tool and ~10^9 parallel tools
      • Heat dissipation and error correction for atomically precise assembly at kilogram scale
      • No bootstrap path from today's scanning probes to self-built nanoscale tools
      plausibleTRL 1
      • The basic operation the assembler repeats billions of times
        ✕3 blockers›
        • Tool-tip reactions are cryogenic, UHV and succeed probabilistically; no reaction set with >99.9% per-step fidelity
        • No demonstrated tooltip recharge cycle, so each tip makes only a handful of bonds
        • Throughput of ~1 operation per minute is ~20 orders of magnitude short of bulk manufacturing
        plausibleTRL 2
      • Most credible bootstrap path is self-assembling designed protein machinery that positions reactants
        ✕1 blocker›
        • Designing catalysis and conformational dynamics
        TRL 6
    • Repair requires devices that sense and act inside tissue, not just circulate
      ✕4 blockers›
      • No onboard power source or computation - behavior is limited to a single preset molecular trigger
      • Immune clearance and protein-corona formation remove most devices within hours
      • Actuation cannot overcome blood flow or cross tissue barriers on command
      • External actuation rigs used in labs do not fit clinical imaging suites
      TRL 3
      • Nucleic-acid scaffolds are the only programmable construction material at this scale today
        ✕3 blockers›
        • Nuclease degradation and cation-dependent unfolding limit in-vivo lifetime to hours without protective coatings
        • Structures generate piconewton forces - far below what mechanical work on cells would need
        • No onboard logic beyond a handful of strand-displacement states
        TRL 5
      • A device you cannot localize in the body cannot be steered or verified
        ✕3 blockers›
        • Optical scattering caps high-resolution imaging at a few millimetres of tissue depth
        • MRI gives depth but not video-rate cell-scale resolution, and excludes magnetic actuation hardware
        • Tracking swarms rather than single objects has no demonstrated method
        TRL 5
      • Sensing and effector modules are designed proteins
        TRL 6
    • Repair must be verified in place, not inferred from outcomes
      TRL 5
  • Revival is impossible unless whole-body vitrification and rewarming can be reversed at all
    ✕4 blockers›
    • Cryoprotectant must reach every tissue through a circulation that stops working as it cools
    • Different tissues need different agent concentrations and cooling rates, so no single protocol fits a whole body
    • Rewarming a 70 kg body uniformly faster than devitrification has no demonstrated mechanism
    • Whole-brain functional recovery after vitrification has never been shown in any species
    plausibleTRL 2
    • A body is a set of organs that must each survive the same protocol
      ✕4 blockers›
      • Rewarming rate must exceed the devitrification threshold everywhere at once - heating uniformity gets worse with volume
      • Thermal-stress cracking appears in organ-scale samples below the glass transition
      • Nanoparticle loading and complete post-warming washout are unproven in large vasculature
      • Brain has never been vitrified and recovered functionally in any species
      TRL 4
      • Vitrification only happens if ice is suppressed throughout the tissue
        ✕3 blockers›
        • Cryoprotectant concentrations that prevent ice (over 50 percent w/v) are chemically toxic over the hours needed to load a large organ
        • Perfusion is uneven - poorly vascularized regions receive too little agent and nucleate ice
        • Devitrification during rewarming happens faster than agents can suppress in large volumes
        TRL 5
    • The brain is the organ whose information must survive, and it sets the protocol's hardest constraint
      ✕3 blockers›
      • Ischemic damage starts within minutes of circulatory arrest, before perfusion can begin
      • Aldehyde fixation may destroy molecular state (phosphorylation, receptor conformation) that could carry memory
      • No assay proves preserved tissue still contains the information an emulation would need
      TRL 4
    • Whole-body loading needs far lower toxicity per unit ice suppression than organ work does
      TRL 5
  • Whatever is preserved must still contain the structural and molecular information the person consisted of
    TRL 4
  • Each organ must be recoverable, not merely intact on histology
    TRL 4
  • Patients are preserved old and sick, so revival implies rejuvenation as well as repair
    ✕3 blockers›
    • No validated surrogate biomarker of biological age, so any whole-body rejuvenation claim needs decade-long outcome trials
    • Hallmarks of aging are correlated; interventions cannot yet be attributed to a specific causal node
    • Mouse lifespan results have repeatedly failed to transfer to longer-lived species
    TRL 3

Who could unlock it

  • Across several requirements:
  • Brain Preservation Foundation 2
  • John Bischof 2
  • NSF ATP-Bio 2
Cell-by-cell in-vivo repairTRL 1bottleneck
  • Wei GaoResearcher, California Institute of Technology
    Built bioresorbable acoustic microrobots that were ultrasound-tracked and magnetically steered to shrink bladder tumours in mice (Science Robotics, 2024), then simplified them into self-targeting bubble bots (Nature Nanotechnology, February 2026)
  • Bjoern HoegbergResearcher, Karolinska Institutet
    Builds DNA origami devices that hide a cytotoxic peptide pattern until a tumour's acidic pH triggers display, killing tumour cells in mice (2024) - the closest thing to a conditional molecular machine acting in a body
  • Bradley NelsonResearcher, Multi-Scale Robotics Lab, ETH Zurich
    Long-running program on magnetically actuated micro- and nanorobots and the control and imaging needed to steer them through real tissue
  • Hao YanResearcher, Biodesign Center for Molecular Design and Biomimetics, Arizona State University
    Pioneer of programmable DNA origami architectures, including origami nanostructures used as triggerable drug carriers in animal models
Desktop molecular assemblerTRL 1bottleneck
  • Robert FreitasResearcher, Institute for Molecular Manufacturing
    Co-author of Kinematic Self-Replicating Machines and of theoretical mechanosynthesis toolsets and nanofactory designs
  • Ralph MerkleResearcher, Institute for Molecular Manufacturing
    Co-developed theoretical assembler and mechanosynthesis designs; co-inventor on CBN Nano's mechanosynthesis patents
  • CBN Nano TechnologiesStartup
    Ottawa company pursuing experimental tip-based mechanosynthesis as a path to nanofactories; holds Freitas/Merkle patents
  • Foresight InstituteProgram
    Nonprofit funding molecular-machine and APM research (~$1.5M grants in 2024) and awarding the Feynman Prizes
Reversible whole-body cryopreservationTRL 2
  • Greg FahyResearcher, 21st Century Medicine
    Developed the M22 cryoprotectant and reported in 2026 ultrastructural and histological preservation of whole mammalian brains by vitrification without aldehyde fixation
  • 21st Century MedicineCompany
    The only company doing primary cryobiology research toward reversible preservation; won the Brain Preservation Foundation small mammal prize for aldehyde-stabilised cryopreservation
  • Brain Preservation FoundationProgram
    Set and judged the small and large mammal brain preservation prizes, which remain the only independent benchmarks in the field
  • Alcor Life Extension FoundationCompany
    Performs whole-body procedures today at roughly 220 thousand dollars (neuro 80 to 90 thousand), all one-way, with no claim of demonstrated reversibility
Synapse-level whole-brain preservationTRL 4
  • Robert McIntyreResearcher, Nectome
    Developed aldehyde-stabilized cryopreservation (Cryobiology 2015) and won the Large Mammal Brain Preservation Prize in 2018
  • NectomeStartup
    Announced in 2026 a field protocol for whole-body preservation at subsynaptic detail, after working on the post-mortem timing problem from 2018 to 2025
  • Sparks Brain PreservationCompany
    Non-profit (formerly Oregon Brain Preservation) offering aldehyde-based preservation; published whole-brain fixed-tissue cryopreservation in PLOS One (2026)
  • Andrew McKenzieResearcher, Sparks Brain Preservation
    Lead on Sparks' studies of immersion fixation and aldehyde-based cryopreservation of human brains (2024-2026)
Organ vitrification and uniform rewarmingTRL 4
  • John BischofResearcher, University of Minnesota
    Directs NSF ATP-Bio and led the September 2026 result vitrifying human-scale pig kidneys for up to 366 days with function recovered on transplant
  • NSF ATP-BioProgram
    NSF Engineering Research Center (EEC-1941543) co-led by Minnesota and Mass General Brigham, pairing the PEZ42 cryoprotectant with radiofrequency nanowarming
  • Erik FingerResearcher, University of Minnesota
    Transplant surgeon who reperfused the nanowarmed pig kidneys in 2026 and reported urine output on the operating table
  • Mehmet TonerResearcher, Massachusetts General Brigham and Harvard Medical School
    Deputy director of ATP-Bio, supplying the microfluidic and biopreservation side of the organ-banking effort

Beyond engineering

  • Preservation can legally begin only after declaration of death, guaranteeing an ischemic interval
  • Centuries-long custodial and financial arrangements with no enforcement precedent
  • No consent framework for a revived person's legal identity, property or obligations